Periprocedural (30-day) risk of myocardial infarction after drug-eluting coronary stent implantation: A meta-analysis comparing cobalt-chromium and stainless steel drug-eluting coronary stents

EuroIntervention

Volumn 6, Issue 8, 2011, Pages 1003-1010

  Moreno, Raul ^a   Jimenez Valero, Santiago ^a   Sanchez Recalde, Angel ^a   Galeote, Guillermo ^a   Calvo, Luis ^a   Martin Reyes, Roberto ^a   Sabate, Manuel ^b   Plaza, Ignacio ^c   Macaya, Carlos ^d   Lopez Sendon, Jose Luis ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Acute myocardial infarction; Coronary stent; Drug eluting stent; Meta analysis

Indexed keywords

CHROMIUM; COBALT; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; STAINLESS STEEL; ZOTAROLIMUS;

ACUTE HEART INFARCTION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DEVICE SAFETY; DRUG ELUTING STENT; HEART DEATH; HEART INFARCTION; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; STENT THROMBOSIS; SURGICAL RISK; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; CHROMIUM ALLOYS; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; RISK ASSESSMENT; RISK FACTORS; STAINLESS STEEL;

EID: 79954480864     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV6I8A173     Document Type: Review

References (28)

1. Moreno R, Fernandez C, Sanchez-Recalde A, Galeote G, Calvo L, Alfonso F, Hernandez R, Sánchez-Aquino R, Angiolillo DJ, Villarreal S, Macaya C, Lopez-Sendon JL. Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. Eur Heart J 2007;28:1583-91. (Pubitemid 47227108)
2. Moreno R. Martin-Reyes R, Jimenez-Valero S, Sanchez-Recalde A, Galeote G, Calvo L, Plaza I, Lopez-Sendon JL. Determining Clinical benefits of drug-eluting coronary stents according to the population risk profile: a meta-regression from 31 randomized trials. Int J Cardiol 2010. In press.
3. Kereiakes DJ, Cox DA, Hermiller JB, Midei MG, Bachinsky WB, Nukta ED, Leon MB, Fink S, Marin L, Lansky AJ; Guidant Multi-Link Vision Stent Registry Investigators. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 2003;92:463-6.
4. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabaté M, Suttorp MJ, Baumgart D, Seyfarth M, PfistererME, Schömig A.. Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. N Engl J Med 2007;356:1030-1039. (Pubitemid 46376803)
5. Stone GW. SPIRIT-IV: a prospective randomized trial of everolimuseluting vs. paclitaxel-eluting stents. Presented in: Transcatheter and Therapeutics intervention 2009. Available in: http://www.tctmd.com/show.aspx?id=84104 (accessed on 6th November, 2009).
6. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, SmitsPC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-09.
7. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease. A randomized trial. JAMA 2008;299:1903-13. (Pubitemid 351574920)
8. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE; ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease. J Am Coll Cardiol 2006;48:2440-7. (Pubitemid 44881222)
9. Kirtane AJ, Patel R, O'Shaughnessy C, Overlie P, McLaurin B, Solomon S, Mauri L, Fitzgerald P, Popma JJ, Kandzari DE, Leon MB. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv 2009;2:967-76.
10. Chevalier B, Di Mario C, Neumann FJ, Ribichini F, Urban P, Popma JJ, Fitzgerald PJ, Cutlip DE, Williams DO, Ormiston J, Grube E, Whitbourn R, Schwartz LB; Zomaxx I investigators. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimusversus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv 2008;1:524-32.
11. Gray WA. ZOMAXX II - A Randomized, Controlled Trial to Evaluate the ZoMaxx Compared to the TAXUS Express2 stent systems in de novo Coronary Artery Lesions. Presented at the EuroPCR 2008. Available in: http://www.tctmd.com/show. aspx?id=67822 (accessed on 6th November, 2009).
12. Park SJ. Comparison of the Efficacy and Safety of Zotarolimus- Eluting Stent versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions: The ZEST Trial. Presented at the American College of Cardiology Session 2008. Available in: http://www.tctmd.com/show.aspx?id=77306 (accessed on 6th November, 2009).
13. Byrne RA, Mehilli J, Lijima R, Schulz S, Pache J, Seyfarth M, Schömig A, Kastrati A. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drugeluting stents. Eur Heart J 2009;30:923-31.
14. Krukoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns W; COSTAR II Investigators Group. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multi-vessel coronary disease. Primary results of the COSTAR (Cobalt Chromium Stent with antiproliferative for restenosis) II study. J Am Coll Cardiol 2008;51:1543-52. (Pubitemid 351512313)
15. th November, 2009).
16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, HamonM, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51. (Pubitemid 46685903)
17. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF, Improving the quality of reports of meta-analysis of randomised controlled trials: the QUOROM statement. Lancet 1999;354:1896-1900.
18. Waksman R, Ghazzal ZM, Baim DS, Steenkiste AR, Yeh W, Detre KM, King SB 3rd. Myocardial infarction as a complication of new interventional devices. Am J Cardiol 1996;78:751-6. (Pubitemid 126657143)
19. Moreno R, Fernandez C, Hernández R, Alfonso F, Angiolillo DJ, Sabaté M, Escaned J, Bañuelos C, Fernández-Ortiz A, Macaya C. Drugeluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-9. (Pubitemid 40342825)
20. Moreno R, Fernandez C, Sanchez A, Galeote G, Sanchez-Aquino R, Alfonso F, Macaya C, López-Sendón JL. Meta-analysis comparing the effect of drug-eluting versus bare metal stents on risk of acute myocardial infarction during follow-up. Am J Cardiol 2007;99:621-5.
21. Blankenship JC, Haldis T, Feit F, Hu T, Kleiman NS, Topol EJ, Lincoff AM; REPLACE-2 Investigators. Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). Am J Cardiol 2006;97:1591-6. (Pubitemid 43737026)
22. Cai Q, Skelding KA, Armstrong AT Jr, Desai D, Wood GC, Blankenship JC. Predictors of periprocedural creatine kinase-myocardial band elevation complicating elective percutaneous coronary intervention. Am J Cardiol 2007;99:616-20.
23. Fuchs S, Gruberg L, Singh S, Stabile E, Duncan C, Wu H, Waksman R, Satler LF, Pichard AD, Kent KM, Kornowski R. Prognostic value of cardiac troponin I re-elevation following percutaneous coronary intervention in high-risk patients with acute coronary syndromes. Am J Cardiol 2001;88:129-33. (Pubitemid 32607697)
24. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary interventions. JAMA 1997;277:461-466. (Pubitemid 27074329)
25. Zahedmanesh H, Lally C. Determination of the influence of stent strut thickness using the finite element method: implications for vascular injury and in-stent restenosis. Med Biol Eng Comput 2009;47:385-93.
26. LaDisa JF Jr, Olson LE, Guler I, Hettrick DA, Audi SH, Kersten JR, Warltier DC, Pagel PS. Stent design properties and deployment ratio influence indexes of wall shear stress: a three-dimensional computational fluid dynamics investigation within a normal artery. J Appl Physiol 2004;97:424-30. (Pubitemid 38802547)
27. Murphy BP, Savage P, McHugh PE, Quinn DF. The stress-strain behavior of coronary stent struts is size dependent. Ann Biomed Eng 2003;31:686-91.
28. Tanigawa J, Barlis P, Dimopoulos K, Dalby M, Moore P, Di Mario C. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. Int J Cardiol 2009;134:180-8.